Intensive chemotherapy followed by stem cell transplantation for patients with poor-risk mds and secondary AML (sAML).

被引：0

作者：

De Witte, T ^{[1
]}

Suciu, S ^{[1
]}

Verhoef, G ^{[1
]}

Labar, B ^{[1
]}

Archimbaud, E ^{[1
]}

Aul, C ^{[1
]}

Selleslag, D ^{[1
]}

Ferrant, A ^{[1
]}

Wijermans, P ^{[1
]}

Mandelli, F ^{[1
]}

Amadori, S ^{[1
]}

Jehn, U ^{[1
]}

Muus, P ^{[1
]}

DeMuynck, H ^{[1
]}

Dardenne, M ^{[1
]}

Zittoun, R ^{[1
]}

Willemze, R ^{[1
]}

Gratwohl, A ^{[1
]}

Apperley, J ^{[1
]}

机构：

[1] Univ Nijmegen Hosp, Dept Hematol, NL-6500 HB Nijmegen, Netherlands

来源：

BLOOD | 1998年 / 92卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2935

引用

页码：714A / 714A

页数：1

共 50 条

[1] Autologous stem cell transplantation (ASCT) for patients with poor risk MDS and secundary AML (sAML)
De Witte, T
Suciu, S
Verhoef, G
Labar, B
Archimbaud, E
Aul, C
Selleslag, D
Ferrant, A
Wijermans, P
Mandelli, F
Amadori, S
Jehn, U
Muus, P
DeMuynck, H
Dardenne, M
Zittoun, R
Willemze, R
Gratwohl, A
Apperley, J
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 282 - 282
[2] The impact of post-remission therapy on outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy with or without stem cell transplantation in a joint study
de Witte, T
Hagemeijer, A
Suciu, S
Belhabri, A
Delforge, M
Aul, C
Aivado, M
Selleslag, D
Schouten, H
Runde, V
Ferrant, A
Kovacsovics, T
Muus, P
Jansen, J
Beeldens, F
Gratwohl, A
Hess, U
Helström-Lindberg, E
Wijermans, P
Ossenkoppele, G
Marie, JP
Willemze, R
Amadori, S
[J]. BONE MARROW TRANSPLANTATION, 2004, 33 : S2 - S2
[3] Intensive remission-induction chemotherapy followed by autologous or allogeneic stem cell transplantation (SCT) for high risk MDS and AML secondary to MDS (SAML) in patients <60 years, a joint study of the eortc LCG and the EBMT.
DeWitte, T
Suciu, S
Boogaerts, M
Labar, B
Archimbaud, E
Runde, V
Selleslag, D
Zittoun, R
VanderLelie, J
Muus, P
DeMuynck, H
Dardenne, M
Willemze, R
Gratwohl, A
Apperley, J
[J]. BLOOD, 1995, 86 (10) : 2458 - 2458
[4] The prognostic impact of cytogenetic features and clonality of patients with poor risk MDS and secondary AML (sAML) after treatment with intensive chemotherapy and stem cell transplantation for the treatment; a joint study of the EORTC, EBMT, SAK, HOVO
de Witte, T
Suciu, S
Delforge, M
Hagemeijer, A
Jotterrand-Bellomo, M
Tigaud, I
Belhabi, A
Aul, C
Avaido, M
Selleslag, D
Schouten, H
Ferrant, A
Amadori, S
Muus, P
Anak, O
Gratwohl, A
Willemze, R
van Dijk, J
[J]. BONE MARROW TRANSPLANTATION, 2001, 27 : S255 - S255
[5] Autologous stem cell transplantation for patients with poor risk MDS and secondary AML (sAML). A joint study of the EORTC, EBMT, SAKK and GIMEMA leukemia groups.
DeWitte, T
Suciu, S
Verhoef, G
Labar, B
Archimbaud, E
Aul, C
Selleslag, D
Ferrant, A
Wijermans, P
Mandelli, F
Amadori, S
Jehn, U
Muus, P
DeMuynck, H
Dardenne, M
Zittoun, R
Willemze, R
Gratwohl, A
Apperley, J
[J]. BLOOD, 1997, 90 (10) : 2594 - 2594
[6] Cytogenetic characteristics predict outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukaemia Groups
de Witte, T
Hagemeijer, A
Suciu, S
Delforge, M
Jotterand-Bellomo, M
Tigaud, I
Belhabri, A
Aul, C
Avaido, M
Selleslag, D
Schouten, H
Ferrant, A
Amadori, S
Muus, P
Anak, O
Beeldens, F
Jansen, J
Hellstrom-Lindberg, E
Gratwohl, A
Willemze, R
[J]. BONE MARROW TRANSPLANTATION, 2002, 29 : S55 - S55
[7] The impact of cytogenetic features and clonality on the prognosis of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation:: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups.
de Witte, T
Suciu, S
van Dijk, J
Delforge, M
Hagemeijer, A
Jotterand-Bellomo, M
Tigaud, I
Belhabri, A
Aul, C
Avaido, M
Selleslag, D
Schouten, H
Ferrant, A
Amadori, S
Muus, P
Anak, Ö
Gratwohl, A
Willemze, R
[J]. BLOOD, 2000, 96 (11) : 546A - +
[8] Syngeneic stem cell transplantation for patients with MDS or sAML
Kröger, N
Brand, R
van Biezen, A
Niederwieser, D
Zander, A
de Witte, T
[J]. BONE MARROW TRANSPLANTATION, 2003, 31 : S182 - S183
[9] Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with MDS or secondary AML
Kröger, N
Schwerdtfeger, R
Bornhäuser, M
Ehninger, G
Runde, V
Beyer, J
Kiehl, M
Schetelig, J
Siegert, W
Schäfer-Eckert, K
Wandt, H
Sayer, HG
Kröger, M
Zabelina, T
Zander, AR
[J]. BONE MARROW TRANSPLANTATION, 2002, 29 : S57 - S57
[10] Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups.
de Witte, T
Hagemeijer, A
Suciu, S
Delforge, M
Jotterand-Bellomo, M
Tigaud, I
Belhabri, A
Aul, C
Avaido, M
Schouten, H
Ferrant, A
Amadori, S
Muus, P
Anak, O
Beeldens, F
Jansen, J
Hellstrom-Lindberg, E
Gratwohl, A
Willemze, R
[J]. BLOOD, 2001, 98 (11) : 619A - 620A

← 1 2 3 4 5 →